Company news

Share this article:
AstraZeneca posted a third quarter sales increase of 3%, to 7.8 billion, according to a company report released today. Emerging markets contributed $1.1 billion – an 18% growth – to the bottom line. In China specifically, the company saw a 35% increase in sales. Crestor profited from its atherosclerosis indication, and US sales of the drug increased by 23%, marking the only branded statin to gain market share in the US this year, according to a company statement. “AstraZeneca has delivered a robust set of results that deliver on our performance commitments despite an increasingly challenging environment for the pharmaceutical sector and business in general,” said David Brennan, CEO, in the report.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters